glp 1 agonist anti inflammatory Anti-inflammatory role of glucagon-like peptide receptor agonists and its clinical implications GLP-1 Receptor Agonists and the
Description
Competition and expansion to improve public reimbursement There is already strong reimbursement coverage of GLP-1s for T2D across US federal, state and commercial payors
The approval is based on the results from the Phase II NOBILITY and Phase III REGENCY studies, where 46.4% of patients receiving Gazyva with standard therapy achieved a complete renal response
A study conducted by Uijl E
Lancet 2016;387:67990.ArticlePubMed 80
36 A post-hoc analysis of the FIGHT trial also demonstrated a trend towards an increase in arrhythmic events in patients on liraglutide (21 versus 39
